Abstracts tagged "Disease Activity"

Abstract Number: 792 • 2013 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients
Maja Bulatovic Calasan¹, Ethan den Boer², Maurits C.F.J. De Rotte³, S.J. Vastert⁴, Sylvia Kamphuis⁵, Robert De Jonge³ and Nico M. Wulffraat⁶, ¹Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁶Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Methotrexate polyglutamates (MTX-PG) could be biomarkers of MTX response and adverse effects and could thus be used as a therapeutic drug monitoring (TDM) tool to steer tailor-made therapeutic…
Abstract Number: 306 • 2013 ACR/ARHP Annual Meeting
Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients
Maria Laura Acosta Felquer¹, Santiago Ruta¹, Javier Rosa², David A. Navarta³, Carla Saucedo¹, Ricardo Garcia-Monaco⁴, Mirtha Sabelli² and Enrique R. Soriano⁵, ¹Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose: Psoriatic arthritis (PsA) manifests clinically in several ways, including arthritis, enthesitis, and dactylitis,. Assessment of disease activity in PsA should ideally record each feature.…
Abstract Number: 2883 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics of Rheumatoid Arthritis Patients with Secondary Sjögren’s Syndrome and Association with Joint Damage
Lindsay E. Brown¹, Michelle A. Frits², Christine K. Iannaccone², Michael E. Weinblatt², Nancy A. Shadick³ and Katherine P. Liao⁴, ¹Internal Medicine, Massachusetts General Hospital, Boston, MA, ²Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Secondary Sjögren's syndrome (sSS) is a common extra-articular manifestation of rheumatoid arthritis (RA). However, the clinical characteristics of this subgroup of patients are not…
Abstract Number: 2456 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Overweight and Obesity and The Relation To Disease Activity, Physical Function and Quality Of Life In Patients With Axial Spondyloarthritis
Fiona Maas¹, Anneke Spoorenberg¹, Eveline van der Veer², Reinhard Bos³, Monique Efde³, Hendrika Bootsma⁴, Elisabeth Brouwer⁵ and Suzanne Arends^3,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Obesity is a growing problem in Western society. It is associated with an increased risk for many disorders, impaired functional capacity, and impaired quality…
Abstract Number: 2246 • 2013 ACR/ARHP Annual Meeting
Patients’ Assessment of the Disease Greatly Influences the Determination of Disease Activity and Remission in Rheumatoid Arthritis
Kenrin Shi^1,2, Kenji Miki^1,3, Masao Yukioka¹, Kosuke Ebina², Shoichi Kaneshiro² and Hideki Yoshikawa², ¹Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ²Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan
Background/Purpose: Recently defined remission criteria of rheumatoid arthritis (RA), Boolean criteria or Simplified Disease Activity Index (SDAI)
Abstract Number: 1669 • 2013 ACR/ARHP Annual Meeting
The Birmingham Vasculitis Activity Score As a Measure Of Disease Activity In Patients With Giant Cell Arteritis
Tanaz A. Kermani¹, David Cuthbertson², Simon Carette³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Kathleen McKinnon-Maksimowicz⁸, Carol McAlear⁹, Paul A. Monach¹⁰, Philip Seo¹¹, Kenneth J. Warrington¹², Steven R. Ytterberg¹³, Peter A Merkel¹⁴ and Eric L. Matteson¹⁵, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, Boston University, Boston, MA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹³Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS), a validated tool for assessment of vasculitis disease activity, in a cohort…
Abstract Number: 1343 • 2013 ACR/ARHP Annual Meeting
Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort
Michael Arnold¹, Vivian P. Bykerk², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, J. Carter Thorne⁶, Edward Keystone⁷ and Janet E. Pope⁸, ¹Medicine/Rheumatology, University College Dublin, Ireland, Dublin, Ireland, ²Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To determine the impact of age on disease and remission in early rheumatoid arthritis (ERA). Methods: Data from the Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting
Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
James Dale¹, Anne Stirling², Iain B. McInnes¹ and Duncan Porter³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Gartnavel General Hospital, Glasgow, United Kingdom, ³Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom
Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
Abstract Number: 219 • 2013 ACR/ARHP Annual Meeting
Contrast-Enhanced Ultrasound Of The Sovraortic Arteries: The Potential Role In Monitoring Disease Activity and Response To Treatment In Large Vessel Vasculitis
Giuseppe Germanò¹, Pierluigi Macchioni¹, Niccolò Possemato² and Carlo Salvarani³, ¹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ³Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: promising data has been recently published about the role of contrast-enhanced ultrasound (CEU) in the diagnosis and follow up of Takayasu arteritis (TA) -1,2-…
Abstract Number: 2869 • 2013 ACR/ARHP Annual Meeting
Changes In Patient-Reported Joint Counts and Composite Indices Can Identify Flare Of Disease Activity In Recent Onset Rheumatoid Arthritis
Karen Visser¹, Susan J. Bartlett^2,3, Clifton O. Bingham III⁴, Ernest Choy⁵, Daming Lin⁶, Juan Xiong⁷, Gilles Boire⁸, Boulos Haraoui⁹, Carol A. Hitchon¹⁰, Edward Keystone¹¹, Janet E. Pope¹², J. Carter Thorne¹³, Diane Tin¹⁴ and Vivian P. Bykerk¹⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁶Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ¹²St Joseph Health Care, London, ON, Canada, ¹³Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁴The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁵Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Patient-reported joint counts (JCs) have been identified as core domains for assessment of flare in rheumatoid arthritis (RA).[1] To assess the responsiveness and discriminative…
Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting
Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care
Denis Choquette¹, Michael Starr², Majed M. Khraishi³, William G. Bensen⁴, Saeed A. Shaikh⁵, Jude F. Rodrigues⁶, Dalton E. Sholter⁷, Maqbool K. Sheriff⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Allen J. Lehman¹⁰, Susan M. Otawa¹⁰, Francois Nantel¹¹ and May Shawi¹², ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Montreal General Hospital, Montreal, QC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Medicine, McMaster University, St Catharines, ON, Canada, ⁶Rheumatology, Windsor, ON, Canada, ⁷Rheumatology Associates, Edmonton, AB, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…
Abstract Number: 2247 • 2013 ACR/ARHP Annual Meeting
Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity
Martin J. Bergman^1,2, Sapna Sangani³, Isabel Castrejón⁴ and Theodore Pincus⁴, ¹Medicine, Drexel University College of Medicine, Philadelphia, PA, ²Taylor Hospital, Ridley Park, PA, ³Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) often report fatigue, but a possible impact of disease on sleep and/or on disease activity are poorly characterized. We…
Abstract Number: 1566 • 2013 ACR/ARHP Annual Meeting
Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Eric F. Morand¹, Kate Franklyn¹, Chak S. Lau², Sandra V. Navarra³, Worawit Louthrenoo⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Singgih Wahono⁷, Shun-Le Chen⁸, Jinou Ou⁹, Alberta Y. Hoi¹ and Mandana Nikpour¹⁰, ¹Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³University of Santo Tomas Hospital, Manila, Philippines, ⁴Dept of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Bandung, Indonesia, ⁷Universitas Brawijaya, Malang, Indonesia, ⁸Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁹3rd Hospital of Sun Yat-san University, Guang Zhou, China, ¹⁰Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia
Background/Purpose: The definitions of low disease activity state (LDAS) and remission as desirable treatment goals in rheumatoid arthritis have been widely applied in research and…
Abstract Number: 1352 • 2013 ACR/ARHP Annual Meeting
What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Soo-Kyung Cho^1,2, Yoon-Kyoung Sung^1,2, Jeeseon Shim³, Chan-Bum Choi^4,5, Jung-Yoon Choe⁶, Won Tae Chung⁷, Seung-Jae Hong⁸, Jae-Bum Jun⁵, Tae-Hwan Kim⁹, Tae-Jong Kim¹⁰, Eun-Mi Koh¹¹, Jisoo Lee¹², Shin-Seok Lee¹⁰, Sung Won Lee¹³, Dae-Hyun Yoo⁵ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹²Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹³Rheumatology, Dong-A University Hospital, Busan, South Korea
Background/Purpose: Clinical remission has now become the treatment goal in rheumatoid arthritis (RA), but it is not common in clinical practice. This study aimed to…
Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].